Loading stock data…
Orthofix Medical Inc. (OFIX)
$9.68-0.10 (-1.02%)
After Hours$9.68+0.00 (+0.00%)· Last close Jun 29
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Orthofix Medical Inc. in the Healthcare sector is trading at $9.68 with a market capitalization of $393M. Wall Street consensus targets $15.00 (4 analysts), implying a +55.0% move over the next 12 months. The stock is currently near its 52-week low of $8.85, remaining 27.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +55.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $196.71M↓ | $219.91M↑ | $205.63M↑ | $203.12M↑ | $193.65M |
| Gross Profit | $139.55M↓ | $156.34M↑ | $148.52M↑ | $139.53M↑ | $121.62M |
| Operating Income | -$13.69M↓ | $1.15M↑ | -$17.47M↓ | -$16.77M↑ | -$49.48M |
| Net Income | -$20.91M↓ | -$2.22M↑ | -$22.80M↓ | -$14.08M↑ | -$53.09M |
Peer Comparison
JNJUNHPFE
Fundamentals
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global L...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$392.90M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.79
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-13.79%
Volume
Today's trading volume
399,623
Recent News
Orthofix (OFIX) Moves 5.1% Higher: Will This Strength Last?
Orthofix (OFIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Orthofix Medical (OFIX) Stock Sees Split Analyst Revisions After CMS Reimbursement Reset
The latest analyst update on Orthofix Medical keeps the model fair value steady at US$15.0 per share, signaling no reset to the core price target despite refreshed assumptions. This stable fair value sits against a backdrop of mixed analyst commentary, with some focusing on the reset in reimbursement expectations for non invasive bone growth stimulators and others stressing the earnings headwind from the new CMS framework. As you read on, you will see how these shifting views shape the...
How The Orthofix Medical (OFIX) Narrative Is Resetting After CMS Cuts And Guidance Changes
Orthofix Medical is back in focus after a recent reset of its fair value estimate, with the price target moving from US$17.25 to US$15.00, a cut of about 13%. That change lines up with a Street narrative that mixes caution and optimism as analysts weigh the impact of CMS reimbursement updates and the company’s revised long term outlook. Read on to see how different analysts are framing this reset and how you can follow the story as it continues to evolve. Wall Street's queuing for one rocket...
Orthofix Medical and 5 More Stocks See Action From Activist Investors
Activists also report to the SEC on BioLife Solutions, Garrett Motion, Life Time Group Holdings, Infleqtion, and CBL Properties.
How The Orthofix Medical (OFIX) Investment Story Is Resetting After New Guidance And Targets
Orthofix Medical is back in focus as Street price targets reset from prior levels of about US$22 to US$24 down into the mid to high teens, with several firms now clustering around the US$17 to US$20 range. Those trims follow Q4 results, updated margin timelines and new guidance. Together, these have led analysts to temper how quickly they expect earnings to build even as they keep generally constructive views on the business. Read on to see what is driving this shift and how to follow the...